Claims
- 1. Compound of formula: ##STR187## in which when Z.sub.1 is C.sub.1 -C.sub.4 alkylene, W is NR.sub.1 R.sub.2, in which R.sub.1 is selected from H and C.sub.1 -C.sub.4 alkyl, and R.sub.2 is selected from H, C.sub.1 -C.sub.4 alkyl, CONQ.sub.1 Q.sub.2 and CSNQ.sub.1 Q.sub.2 in which Q.sub.1 and Q.sub.2 are independently selected from H and C.sub.1 -C.sub.4 alkyl, SO.sub.2 Q.sub.3 in which Q3 is C.sub.1 -C.sub.4 alkyl, COOQ.sub.4 in which Q.sub.4 is selected from C.sub.1 -C.sub.4 aikyl and benzyl, or R.sub.1 and R.sub.2 taken together form with N a saturated heterocycle morpholine, pyrrolidine, piperidine, piperazine or 4-(C.sub.1 -C.sub.3)alkyl-piperazine; or W is N(O)R.sub.1 R.sub.2 in which R.sub.1, R.sub.2 independently selected from H and C.sub.1 -C.sub.4 alkyl; or W is selected from the group consisting of C.sub.1 -C.sub.4 alkoxy, and C.sub.1 - C.sub.4 thioalkoxy;
- when Z.sub.1 is phenylene, W is NR.sub.1 R.sub.2 in which R.sub.1 and R.sub.2 are independently selected from H and C.sub.1 -C.sub.4 alkyl;
- Z.sub.2 is C.sub.1 -C.sub.4 alkylene;
- R.sub.3 is selected from H, C.sub.1 -C.sub.8 alkyl and halogen;
- Ar.sub.1 is selected from phenyl optionally substituted by one or more groups selected from halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub. 4 thioalkoxy, hydroxy, COOQ.sub.6 in which Q.sub.6 is C.sub.1 -C.sub.4 alkyl, carboxamido, cyano, amino, acetamido, nitro, trifluoromethyl; naphtyl, benzyl and cyclohexyl;
- Ar.sub.2 is pyridyl, optionally substituted by a radical selected from C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and halogen; or a pharmaceutically acceptable acid or base salt thereof.
- 2. Compound according to claim 1 of formula I in which Ar.sub.1 is at least ortho-substituted phenyl.
- 3. Compound according to claim 1 of formula I in which Ar.sub.1 is phenyl without an ortho substituent and R.sub.3 is C.sub.1 -C.sub.3 alkyl.
- 4. Compound according to claim 1 in which Z.sub.1 is C.sub.1 -C.sub.4 alkylene and W is NR.sub.1 R.sub.2.
- 5. Compound according to claim 1 in which Z.sub.1 is C.sub.2 -C.sub.4 alkylene, W is NR.sub.1 R.sub.2 and Ar.sub.2 is selected from 2-pyridyl and 3-pyridyl.
- 6. Compound according to claim 1 of formula I in which W is selected from C.sub.1 -C.sub.2 alkoxy and C.sub.1 -C.sub.2 thioalkoxy.
- 7. Compound according to claim 2 in which W is selected from C.sub.1 -C.sub.2 alkoxy and C.sub.1 -C.sub.2 thioalkoxy.
- 8. Compound according to claim 3 in which W is selected from C.sub.1 -C.sub.2 alkoxy and C.sub.1 -C.sub.2 thioalkoxy.
- 9. Compound according to claim 4 in which W is selected from C.sub.1 -C.sub.2 alkoxy and C.sub.1 -C.sub.2 thioalkoxy.
- 10. Compound according to claim 5 in which W is selected from C.sub.1 -C.sub.2 alkoxy and C.sub.1 -C.sub.2 thioalkoxy.
- 11. Compound according to claim 1 of formula I in which W is an amino group.
- 12. Compound according to claim 2 in which W is an amino group.
- 13. Compound according to claim 3 in which W is an amino group.
- 14. Compound according to claim 4 in which W is an amino group.
- 15. Compound according to claim 5 in which W is an amino group.
- 16. Compound according to claim 1 of formula I in which Z.sub.1 is C.sub.2 -C.sub.3 alkylene.
- 17. Compound according to claim 2 in which Z.sub.1 is C.sub.2 -C.sub.3 alkylene.
- 18. Compound according to claim 3 in which Z.sub.1 is C.sub.2 -C.sub.3 alkylene.
- 19. Compound according to claim 4 in which Z.sub.1 is C.sub.2 -C.sub.3 alkylene.
- 20. Compound according to claim 5 in which Z.sub.1 is C.sub.2 -C.sub.3 alkylene.
- 21. Compound according to claim 1 selected from -2- (N-[2-N', N'-dimethylaminoethyl]N- [3-pyridylmethyl ]-amino) 4-(2,4,6-triisopropylphenyl)thiazole,-2-(N-[2-N',N'dimethylaminoethyl ]N-[3-pyridylmethyl]-amino)4-(2,4,6trimethylphenyl) thiazole,-2-(N-[2-N'-dimethylaminoethyl]N-[3-pyridylmethyl ]-amino)4-(2,4-dichlorophenyl)5-methyl thiazole, -2-(N-[2-N', N'-dimethylaminoethyl]N-[3-pyridylmethyl]amino)4-(2,4,6-triisopropylphenyl)5-chloro thiazole, -2-(N-[2-N', N'-dimethylaminoethyl]N-[3-pyridylmethyl]amino) 4-(2,4,6-triisopropylphenyl)5-bromo thiazole, or a pharmaceutically acceptable salt thereof.
- 22. A method for treating a disease associated with an excess of platelet-aggregating-factor-acether comprising administering to a patient in need thereof an effective amount of the compound of claim 1, in admixture with a pharmaceutically acceptable carrier.
- 23. Pharmaceutical composition comprising an effective amount of a compound according to claim 1, in which the salts are pharmaceutically acceptable, and at least one excipient.
Priority Claims (1)
Number |
Date |
Country |
Kind |
89 17491 |
Dec 1989 |
FRX |
|
Parent Case Info
This application is a continuation of U.S. application Ser. No. 07/743,309 filed as PCT/FR90/00970, Dec. 28, 1990, now abandoned.
Foreign Referenced Citations (3)
Number |
Date |
Country |
0149884 |
Aug 1984 |
EPX |
0283390 |
Sep 1988 |
EPX |
880749 |
Jun 1953 |
DEX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
743309 |
Aug 1991 |
|